Initial Ph II 2b Results of Elios' Personalized Cancer Vaccine for the Treatment of Melanoma Look Promising

Elios Therapeutics, a biopharmaceutical company developing particle-delivered, dendritic cell vaccines in the oncology arena, today presented initial open-label results from the ongoing Phase 2b clinical trial of the TLPLDC (tumor lysate, particle-loaded, dendritic cell) vaccine in patients with stage III and IV (resected) melanoma.